Histone Deacetylase Inhibition Attenuates Transcriptional Activity of Mineralocorticoid Receptor Through Its Acetylation and Prevents Development of Hypertension
RATIONALE:Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate–induced hypertensive rats and spontaneously hypertensive rats. However, the molecular mechanism remains elusive. OBJECTIVE:We hypothesized that HDAC inhibition attenu...
Saved in:
Published in | Circulation research Vol. 112; no. 7; pp. 1004 - 1012 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Heart Association, Inc
29.03.2013
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | RATIONALE:Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate–induced hypertensive rats and spontaneously hypertensive rats. However, the molecular mechanism remains elusive.
OBJECTIVE:We hypothesized that HDAC inhibition attenuates transcriptional activity of mineralocorticoid receptor (MR) through its acetylation and prevents development of hypertension in deoxycorticosterone acetate–induced hypertensive rats.
METHODS AND RESULTS:Expression of MR target genes was measured by quantitative real-time polymerase chain reaction. Recruitment of MR and RNA polymerase II on promoters of target genes was analyzed by chromatin immunoprecipitation assay. Live cell imaging was performed for visualization of nuclear translocation of MR. MR acetylation was determined by Western blot with anti-acetyl-lysine antibody after immunoprecipitation with anti-MR antibody. Transcriptional activity of MR was determined by luciferase assay. For establishment of a hyperaldosteronism animal, Sprague-Dawley rats underwent uninephrectomy and received subcutaneous injection of 40 mg/kg per week of deoxycorticosterone acetate and drinking water containing 1% NaCl. Treatment with a HDAC class I inhibitor resulted in reduced expression of MR target genes in accordance with reduced recruitment of MR and RNA polymerase II on promoters of target genes. HDAC inhibition promoted MR acetylation, leading to decreased transcriptional activity of MR. Knockdown or inhibition of HDAC3 resulted in reduced expression of MR target genes induced by mineralocorticoids.
CONCLUSIONS:These results indicate that HDAC inhibition attenuates transcriptional activity of MR through its acetylation and prevents development of hypertension in deoxycorticosterone acetate–induced hypertensive rats. |
---|---|
AbstractList | RATIONALE:Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate–induced hypertensive rats and spontaneously hypertensive rats. However, the molecular mechanism remains elusive.
OBJECTIVE:We hypothesized that HDAC inhibition attenuates transcriptional activity of mineralocorticoid receptor (MR) through its acetylation and prevents development of hypertension in deoxycorticosterone acetate–induced hypertensive rats.
METHODS AND RESULTS:Expression of MR target genes was measured by quantitative real-time polymerase chain reaction. Recruitment of MR and RNA polymerase II on promoters of target genes was analyzed by chromatin immunoprecipitation assay. Live cell imaging was performed for visualization of nuclear translocation of MR. MR acetylation was determined by Western blot with anti-acetyl-lysine antibody after immunoprecipitation with anti-MR antibody. Transcriptional activity of MR was determined by luciferase assay. For establishment of a hyperaldosteronism animal, Sprague-Dawley rats underwent uninephrectomy and received subcutaneous injection of 40 mg/kg per week of deoxycorticosterone acetate and drinking water containing 1% NaCl. Treatment with a HDAC class I inhibitor resulted in reduced expression of MR target genes in accordance with reduced recruitment of MR and RNA polymerase II on promoters of target genes. HDAC inhibition promoted MR acetylation, leading to decreased transcriptional activity of MR. Knockdown or inhibition of HDAC3 resulted in reduced expression of MR target genes induced by mineralocorticoids.
CONCLUSIONS:These results indicate that HDAC inhibition attenuates transcriptional activity of MR through its acetylation and prevents development of hypertension in deoxycorticosterone acetate–induced hypertensive rats. RATIONALEInhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate-induced hypertensive rats and spontaneously hypertensive rats. However, the molecular mechanism remains elusive.OBJECTIVEWe hypothesized that HDAC inhibition attenuates transcriptional activity of mineralocorticoid receptor (MR) through its acetylation and prevents development of hypertension in deoxycorticosterone acetate-induced hypertensive rats.METHODS AND RESULTSExpression of MR target genes was measured by quantitative real-time polymerase chain reaction. Recruitment of MR and RNA polymerase II on promoters of target genes was analyzed by chromatin immunoprecipitation assay. Live cell imaging was performed for visualization of nuclear translocation of MR. MR acetylation was determined by Western blot with anti-acetyl-lysine antibody after immunoprecipitation with anti-MR antibody. Transcriptional activity of MR was determined by luciferase assay. For establishment of a hyperaldosteronism animal, Sprague-Dawley rats underwent uninephrectomy and received subcutaneous injection of 40 mg/kg per week of deoxycorticosterone acetate and drinking water containing 1% NaCl. Treatment with a HDAC class I inhibitor resulted in reduced expression of MR target genes in accordance with reduced recruitment of MR and RNA polymerase II on promoters of target genes. HDAC inhibition promoted MR acetylation, leading to decreased transcriptional activity of MR. Knockdown or inhibition of HDAC3 resulted in reduced expression of MR target genes induced by mineralocorticoids.CONCLUSIONSThese results indicate that HDAC inhibition attenuates transcriptional activity of MR through its acetylation and prevents development of hypertension in deoxycorticosterone acetate-induced hypertensive rats. Rationale: Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate–induced hypertensive rats and spontaneously hypertensive rats. However, the molecular mechanism remains elusive. Objective: We hypothesized that HDAC inhibition attenuates transcriptional activity of mineralocorticoid receptor (MR) through its acetylation and prevents development of hypertension in deoxycorticosterone acetate–induced hypertensive rats. Methods and Results: Expression of MR target genes was measured by quantitative real-time polymerase chain reaction. Recruitment of MR and RNA polymerase II on promoters of target genes was analyzed by chromatin immunoprecipitation assay. Live cell imaging was performed for visualization of nuclear translocation of MR. MR acetylation was determined by Western blot with anti-acetyl-lysine antibody after immunoprecipitation with anti-MR antibody. Transcriptional activity of MR was determined by luciferase assay. For establishment of a hyperaldosteronism animal, Sprague-Dawley rats underwent uninephrectomy and received subcutaneous injection of 40 mg/kg per week of deoxycorticosterone acetate and drinking water containing 1% NaCl. Treatment with a HDAC class I inhibitor resulted in reduced expression of MR target genes in accordance with reduced recruitment of MR and RNA polymerase II on promoters of target genes. HDAC inhibition promoted MR acetylation, leading to decreased transcriptional activity of MR. Knockdown or inhibition of HDAC3 resulted in reduced expression of MR target genes induced by mineralocorticoids. Conclusions: These results indicate that HDAC inhibition attenuates transcriptional activity of MR through its acetylation and prevents development of hypertension in deoxycorticosterone acetate–induced hypertensive rats. Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate-induced hypertensive rats and spontaneously hypertensive rats. However, the molecular mechanism remains elusive. We hypothesized that HDAC inhibition attenuates transcriptional activity of mineralocorticoid receptor (MR) through its acetylation and prevents development of hypertension in deoxycorticosterone acetate-induced hypertensive rats. Expression of MR target genes was measured by quantitative real-time polymerase chain reaction. Recruitment of MR and RNA polymerase II on promoters of target genes was analyzed by chromatin immunoprecipitation assay. Live cell imaging was performed for visualization of nuclear translocation of MR. MR acetylation was determined by Western blot with anti-acetyl-lysine antibody after immunoprecipitation with anti-MR antibody. Transcriptional activity of MR was determined by luciferase assay. For establishment of a hyperaldosteronism animal, Sprague-Dawley rats underwent uninephrectomy and received subcutaneous injection of 40 mg/kg per week of deoxycorticosterone acetate and drinking water containing 1% NaCl. Treatment with a HDAC class I inhibitor resulted in reduced expression of MR target genes in accordance with reduced recruitment of MR and RNA polymerase II on promoters of target genes. HDAC inhibition promoted MR acetylation, leading to decreased transcriptional activity of MR. Knockdown or inhibition of HDAC3 resulted in reduced expression of MR target genes induced by mineralocorticoids. These results indicate that HDAC inhibition attenuates transcriptional activity of MR through its acetylation and prevents development of hypertension in deoxycorticosterone acetate-induced hypertensive rats. |
Author | Lee, Hae-Ahm Kim, In Kyeom Cho, Hyun-Min Kim, Sang-Yeob Lee, Dong-Youb Iwasaki, Yasumasa |
AuthorAffiliation | From the Department of Pharmacology (H.-A.L., D.-Y.L., H.-M.C., I.K.), Cardiovascular Research Institute (H.-A.L., I.K.), Cell and Matrix Research Institute (H.-A.L., S.-Y.K., I.K.), and Department of Biochemistry and Cell Biology (S.-Y.K.), Kyungpook National University School of Medicine, Daegu, Republic of Korea; and Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan (Y.I.) |
AuthorAffiliation_xml | – name: From the Department of Pharmacology (H.-A.L., D.-Y.L., H.-M.C., I.K.), Cardiovascular Research Institute (H.-A.L., I.K.), Cell and Matrix Research Institute (H.-A.L., S.-Y.K., I.K.), and Department of Biochemistry and Cell Biology (S.-Y.K.), Kyungpook National University School of Medicine, Daegu, Republic of Korea; and Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan (Y.I.) |
Author_xml | – sequence: 1 givenname: Hae-Ahm surname: Lee fullname: Lee, Hae-Ahm organization: From the Department of Pharmacology (H.-A.L., D.-Y.L., H.-M.C., I.K.), Cardiovascular Research Institute (H.-A.L., I.K.), Cell and Matrix Research Institute (H.-A.L., S.-Y.K., I.K.), and Department of Biochemistry and Cell Biology (S.-Y.K.), Kyungpook National University School of Medicine, Daegu, Republic of Korea; and Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Nankoku, Japan (Y.I.) – sequence: 2 givenname: Dong-Youb surname: Lee fullname: Lee, Dong-Youb – sequence: 3 givenname: Hyun-Min surname: Cho fullname: Cho, Hyun-Min – sequence: 4 givenname: Sang-Yeob surname: Kim fullname: Kim, Sang-Yeob – sequence: 5 givenname: Yasumasa surname: Iwasaki fullname: Iwasaki, Yasumasa – sequence: 6 givenname: In surname: Kim middlename: Kyeom fullname: Kim, In Kyeom |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23421989$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUU1vEzEQtVARTQM_AeQjly322mbj4yptSaRWoBDOK8c7Zg2OvdjeVvk5_FOcppQjp9HTvA_NvAt05oMHhN5ScknpR_phud4sN9df21VbMLtkhJKGvkAzKmpecdHQMzQjhMiqYYyco4uUfhBCOavlK3ReM15TuZAz9HtlUy7O-AqUhnxwKgFe-8HubLbB4zZn8JPKkPA2Kp90tONxoRxudbb3Nh9wMPjOeojKBR1itjrYHm9Aw5hDxNshhun7gNc5FcljxKOz8j3-EuEefFlclenCuC_gaLc6jBBLcCrE1-ilUS7Bm6c5R99urrfLVXX7-dN62d5WulxMK9UraahSQhBeg16AViCU4kIYtgAlmDFES9bXZtcb1Te9NI3ecWMoYTUXks3R-5PvGMOvCVLu9jZpcE55CFPqKKtpIzkv_5wjcaLqGFKKYLox2r2Kh46S7thO96-dgll3aqfo3j1FTLs99M-qv3UUgjwRHoLLENNPNz1A7AZQLg__Mf8DI1ql2g |
CitedBy_id | crossref_primary_10_1016_j_steroids_2014_05_017 crossref_primary_10_1016_j_bbadis_2016_08_011 crossref_primary_10_1038_s41569_019_0235_9 crossref_primary_10_1016_j_semnephrol_2020_01_005 crossref_primary_10_1074_jbc_M113_505115 crossref_primary_10_1146_annurev_pharmtox_010814_124302 crossref_primary_10_2174_1570180819666220527160528 crossref_primary_10_18632_oncotarget_2371 crossref_primary_10_4196_kjpp_2016_20_5_477 crossref_primary_10_1111_jcmm_14188 crossref_primary_10_3346_jkms_2017_32_11_1738 crossref_primary_10_1016_j_vph_2015_04_006 crossref_primary_10_48198_NJPAS_20_A07 crossref_primary_10_2174_1389557522666220217103441 crossref_primary_10_1016_j_ejphar_2015_10_035 crossref_primary_10_1097_JCP_0000000000000510 crossref_primary_10_1111_febs_16695 crossref_primary_10_1210_me_2014_1002 crossref_primary_10_1371_journal_pone_0136801 crossref_primary_10_1016_j_compbiomed_2023_107481 crossref_primary_10_1016_j_heliyon_2024_e33997 crossref_primary_10_1038_s41598_019_52762_w crossref_primary_10_1042_BSR20193995 crossref_primary_10_1186_s40885_019_0118_8 crossref_primary_10_1038_s41440_020_00548_3 crossref_primary_10_3109_13813455_2016_1151892 crossref_primary_10_4068_cmj_2016_52_1_1 crossref_primary_10_1016_j_jsbmb_2014_04_015 crossref_primary_10_1096_fj_201801151R crossref_primary_10_3390_life14010023 crossref_primary_10_1016_j_biopha_2020_110503 crossref_primary_10_3389_fmed_2020_00475 crossref_primary_10_1016_j_pharmthera_2014_02_012 crossref_primary_10_1016_j_steroids_2023_109291 crossref_primary_10_1161_CIRCRESAHA_118_311342 crossref_primary_10_1097_FJC_0000000000001372 crossref_primary_10_11131_2014_101092 crossref_primary_10_1002_hep_27940 crossref_primary_10_4196_kjpp_2020_24_4_319 crossref_primary_10_1111_1440_1681_12377 crossref_primary_10_1111_1440_1681_12614 crossref_primary_10_1016_j_biopha_2020_111162 crossref_primary_10_1007_s00210_019_01749_5 crossref_primary_10_1002_cai2_114 crossref_primary_10_3389_fendo_2021_679655 crossref_primary_10_3390_foods10061288 crossref_primary_10_1016_j_pharmthera_2016_07_004 crossref_primary_10_1097_HJH_0000000000003143 crossref_primary_10_3390_bioengineering9120798 crossref_primary_10_1111_jsm_12522 crossref_primary_10_1210_en_2014_1565 crossref_primary_10_1016_j_ejmech_2018_08_081 crossref_primary_10_1016_j_jare_2024_02_003 crossref_primary_10_1007_s00210_016_1246_2 crossref_primary_10_4070_kcj_2016_0266 crossref_primary_10_1111_and_12465 crossref_primary_10_1016_j_bcp_2022_115111 crossref_primary_10_4196_kjpp_2018_22_1_23 crossref_primary_10_1038_s41440_019_0332_5 crossref_primary_10_1161_HYPERTENSIONAHA_118_11171 crossref_primary_10_1111_bph_14837 crossref_primary_10_1111_jog_15844 crossref_primary_10_1038_ijo_2017_166 crossref_primary_10_1210_en_2015_2055 crossref_primary_10_1530_JME_15_0122 crossref_primary_10_1152_ajpendo_00267_2017 crossref_primary_10_1021_acs_jmedchem_0c01676 crossref_primary_10_1016_j_ejphar_2021_173988 crossref_primary_10_3390_ijms18081794 crossref_primary_10_1007_s11010_020_04031_y crossref_primary_10_1161_HYPERTENSIONAHA_124_22072 crossref_primary_10_1016_j_bbadis_2015_05_008 crossref_primary_10_3390_ijms232012592 crossref_primary_10_1161_HYPERTENSIONAHA_123_21755 crossref_primary_10_4196_kjpp_2015_19_5_467 crossref_primary_10_1155_2017_8208065 crossref_primary_10_3390_ijms19113539 crossref_primary_10_3389_fmolb_2021_667990 crossref_primary_10_33549_physiolres_934110 crossref_primary_10_1161_CIRCRESAHA_114_305054 crossref_primary_10_1161_HYPERTENSIONAHA_115_05962 crossref_primary_10_1111_bph_15719 crossref_primary_10_1124_mol_114_096974 crossref_primary_10_1097_HJH_0000000000001081 crossref_primary_10_1155_2014_641979 crossref_primary_10_5483_BMBRep_2015_48_3_242 |
Cites_doi | 10.1210/er.2007-0030 10.1210/me.2004-0537 10.1152/ajpheart.01096.2001 10.1253/circj.CJ-09-0050 10.1016/j.molcel.2006.04.019 10.1111/j.1471-4159.2008.05575.x 10.1158/1541-7786.MCR-07-0324 10.1016/j.biopha.2006.07.082 10.1111/j.1476-5381.2010.00637.x 10.1038/nm.1879 10.1161/hypertensionaha.110.154567 10.1210/endo.138.3.4994 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H 10.1210/en.2004-1674 10.1074/jbc.M100800200 10.1056/NEJM199909023411001 10.1074/jbc.M110.185488 10.1161/01.hyp.0000174593.88899.68 10.1161/01.res.0000037983.07158.b1 10.1161/circresaha.111.258426 10.1073/pnas.0407008101 10.1016/S1097-2765(01)00414-2 10.1056/NEJMoa030207 10.1002/jcb.21640 10.1158/0008-5472.CAN-03-0799 10.1038/47412 10.1210/jcem.83.12.5470 10.1042/bse0400011 10.1621/nrs.05012 10.1146/annurev.biochem.76.052705.162114 10.1016/j.cell.2011.03.043 10.1210/me.2005-0089 10.1161/hypertensionaha.111.182428 10.1096/fj.08-117697 10.1210/me.2010-0170 10.1161/circulationaha.106.625467 10.1074/jbc.M409053200 10.1016/j.bcp.2006.05.024 |
ContentType | Journal Article |
Copyright | 2013 American Heart Association, Inc. |
Copyright_xml | – notice: 2013 American Heart Association, Inc. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1161/CIRCRESAHA.113.301071 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4571 |
EndPage | 1012 |
ExternalDocumentID | 10_1161_CIRCRESAHA_113_301071 23421989 10.1161/CIRCRESAHA.113.301071 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - .Z2 01R 0R 1J1 29B 2WC 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O 7O~ AAAXR AAMOA AAMTA AAPBV AARTV AAXQO ABBUW ABFLS ABOCM ABXVJ ABZAD ACDDN ACEWG ACGFS ACPRK ACWDW ACWRI ACXNZ ADACO ADBBV AE3 AENEX AFUWQ AHMBA AHULI AHVBC AIJEX AJIOK ALMA_UNASSIGNED_HOLDINGS AMJPA ASCII AWKKM BAWUL BOYCO BQLVK C45 CS3 DIK DU5 DUNZO E.X E3Z EBS EJD EX3 F2K F2L F2M F2N F5P FL- FRP FW0 GX1 H0 H0~ H13 HZ IKYAY IN IN~ JK3 JK8 K8S KD2 KMI KQ8 L-C L7B LI0 N9A N~7 N~B O0- O9- OAG OAH OB2 ODA OHASI OK1 OL1 OLG OLH OLU OLV OLW OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OWW OWY OXXIT P2P PQEST PQQKQ RAH RHF RIG RLZ RSW S4R S4S UPT V2I WH7 WOQ WOW X X3V X3W Z2 ZA5 --- -~X .-D .3C 0R~ 18M AAAAV AAGIX AAHPQ AAIQE AASOK ABDIG ABJNI ABQRW ACCJW ACGFO ACILI ACNWC ADGGA ADHPY AE6 AEETU AFDTB AGINI AHOMT AHQNM AINUH AJNWD AMNEI CGR CUY CVF DIWNM ECM EIF FCALG HZ~ IKREB NPM T8P TEORI TR2 VVN W3M W8F YFH YOC ZFV ZZMQN AAYXX AJZMW CITATION 7X8 |
ID | FETCH-LOGICAL-c5241-ada9f1aa55042ec8ecae5aa455f38ea53ff0c93d2fbdfad7d9f7cb4ff10324593 |
ISSN | 0009-7330 |
IngestDate | Fri Aug 16 02:02:52 EDT 2024 Fri Aug 23 03:51:58 EDT 2024 Thu May 23 23:17:25 EDT 2024 Thu Aug 13 19:50:26 EDT 2020 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c5241-ada9f1aa55042ec8ecae5aa455f38ea53ff0c93d2fbdfad7d9f7cb4ff10324593 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.113.301071 |
PMID | 23421989 |
PQID | 1321794473 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_1321794473 crossref_primary_10_1161_CIRCRESAHA_113_301071 pubmed_primary_23421989 wolterskluwer_health_10_1161_CIRCRESAHA_113_301071 |
ProviderPackageCode | L-C C45 7O~ AARTV OLH ASCII OLG AAMOA ODA ABZAD ABBUW JK3 JK8 H0~ 1J1 OLV OLU OLW OLZ OLY F2K F2M F2L F2N OHASI AHVBC FL- KMI K8S OVLEI AJIOK OPUJH V2I S4R S4S 4Q1 DUNZO OAG 4Q2 OVDNE 4Q3 AMJPA OAH OVD 71W AHULI OB2 ACEWG .Z2 N~7 IKYAY OVIDH AWKKM 40H N~B X3V X3W ACDDN ACWRI BOYCO AIJEX AAXQO AAMTA AAAXR E.X OWW OWY 01R ACXNZ OL1 ABXVJ IN~ KD2 OXXIT 77Y ACWDW FW0 |
PublicationCentury | 2000 |
PublicationDate | 2013-March-29 2013-Mar-29 2013-03-29 20130329 |
PublicationDateYYYYMMDD | 2013-03-29 |
PublicationDate_xml | – month: 03 year: 2013 text: 2013-March-29 day: 29 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Circulation research |
PublicationTitleAlternate | Circ Res |
PublicationYear | 2013 |
Publisher | American Heart Association, Inc |
Publisher_xml | – name: American Heart Association, Inc |
References | e_1_3_5_28_2 e_1_3_5_27_2 e_1_3_5_26_2 e_1_3_5_25_2 e_1_3_5_24_2 e_1_3_5_23_2 e_1_3_5_22_2 e_1_3_5_21_2 e_1_3_5_29_2 e_1_3_5_2_2 e_1_3_5_40_2 e_1_3_5_8_2 e_1_3_5_20_2 e_1_3_5_7_2 e_1_3_5_9_2 e_1_3_5_4_2 e_1_3_5_3_2 e_1_3_5_6_2 e_1_3_5_5_2 e_1_3_5_17_2 e_1_3_5_39_2 e_1_3_5_16_2 e_1_3_5_38_2 e_1_3_5_15_2 e_1_3_5_37_2 e_1_3_5_14_2 e_1_3_5_36_2 e_1_3_5_12_2 e_1_3_5_35_2 e_1_3_5_13_2 e_1_3_5_34_2 e_1_3_5_10_2 e_1_3_5_11_2 e_1_3_5_32_2 Fuqua SA (e_1_3_5_33_2) 2000; 60 e_1_3_5_19_2 e_1_3_5_18_2 e_1_3_5_31_2 e_1_3_5_30_2 |
References_xml | – ident: e_1_3_5_16_2 doi: 10.1210/er.2007-0030 – ident: e_1_3_5_31_2 doi: 10.1210/me.2004-0537 – ident: e_1_3_5_19_2 doi: 10.1152/ajpheart.01096.2001 – ident: e_1_3_5_30_2 doi: 10.1253/circj.CJ-09-0050 – ident: e_1_3_5_12_2 doi: 10.1016/j.molcel.2006.04.019 – ident: e_1_3_5_23_2 doi: 10.1111/j.1471-4159.2008.05575.x – ident: e_1_3_5_22_2 doi: 10.1158/1541-7786.MCR-07-0324 – ident: e_1_3_5_14_2 doi: 10.1016/j.biopha.2006.07.082 – ident: e_1_3_5_2_2 doi: 10.1111/j.1476-5381.2010.00637.x – ident: e_1_3_5_40_2 doi: 10.1038/nm.1879 – ident: e_1_3_5_3_2 doi: 10.1161/hypertensionaha.110.154567 – ident: e_1_3_5_36_2 doi: 10.1210/endo.138.3.4994 – ident: e_1_3_5_24_2 doi: 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H – ident: e_1_3_5_37_2 doi: 10.1210/en.2004-1674 – ident: e_1_3_5_34_2 doi: 10.1074/jbc.M100800200 – ident: e_1_3_5_38_2 doi: 10.1056/NEJM199909023411001 – ident: e_1_3_5_11_2 doi: 10.1074/jbc.M110.185488 – ident: e_1_3_5_18_2 doi: 10.1161/01.hyp.0000174593.88899.68 – ident: e_1_3_5_8_2 doi: 10.1161/01.res.0000037983.07158.b1 – ident: e_1_3_5_20_2 doi: 10.1161/circresaha.111.258426 – ident: e_1_3_5_28_2 doi: 10.1073/pnas.0407008101 – ident: e_1_3_5_10_2 doi: 10.1016/S1097-2765(01)00414-2 – ident: e_1_3_5_39_2 doi: 10.1056/NEJMoa030207 – ident: e_1_3_5_32_2 doi: 10.1002/jcb.21640 – ident: e_1_3_5_21_2 doi: 10.1158/0008-5472.CAN-03-0799 – ident: e_1_3_5_4_2 doi: 10.1038/47412 – ident: e_1_3_5_26_2 doi: 10.1210/jcem.83.12.5470 – ident: e_1_3_5_13_2 doi: 10.1042/bse0400011 – ident: e_1_3_5_17_2 doi: 10.1621/nrs.05012 – volume: 60 start-page: 4026 year: 2000 ident: e_1_3_5_33_2 article-title: A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. publication-title: Cancer Res contributor: fullname: Fuqua SA – ident: e_1_3_5_5_2 doi: 10.1146/annurev.biochem.76.052705.162114 – ident: e_1_3_5_9_2 doi: 10.1016/j.cell.2011.03.043 – ident: e_1_3_5_29_2 doi: 10.1210/me.2005-0089 – ident: e_1_3_5_27_2 doi: 10.1161/hypertensionaha.111.182428 – ident: e_1_3_5_25_2 doi: 10.1096/fj.08-117697 – ident: e_1_3_5_35_2 doi: 10.1210/me.2010-0170 – ident: e_1_3_5_6_2 doi: 10.1161/circulationaha.106.625467 – ident: e_1_3_5_7_2 doi: 10.1074/jbc.M409053200 – ident: e_1_3_5_15_2 doi: 10.1016/j.bcp.2006.05.024 |
SSID | ssj0014329 |
Score | 2.4375956 |
Snippet | RATIONALE:Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate–induced hypertensive rats... Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate-induced hypertensive rats and... Rationale: Inhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate–induced hypertensive... RATIONALEInhibition of histone deacetylases (HDACs) results in attenuated development of hypertension in deoxycorticosterone acetate-induced hypertensive rats... |
SourceID | proquest crossref pubmed wolterskluwer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1004 |
SubjectTerms | Acetylation - drug effects Aldosterone - pharmacology Animals Desoxycorticosterone - pharmacology Disease Models, Animal DNA Polymerase II - metabolism Enzyme Inhibitors - pharmacology Gene Expression - drug effects HEK293 Cells Histone Deacetylase Inhibitors - pharmacology Histone Deacetylases - genetics Histone Deacetylases - metabolism Humans Hypertension, Renal - chemically induced Hypertension, Renal - prevention & control Male Mineralocorticoids - pharmacology Nephrectomy Promoter Regions, Genetic - genetics Rats Rats, Sprague-Dawley Receptors, Mineralocorticoid - genetics Receptors, Mineralocorticoid - metabolism Transcription, Genetic - drug effects Valproic Acid - pharmacology |
Title | Histone Deacetylase Inhibition Attenuates Transcriptional Activity of Mineralocorticoid Receptor Through Its Acetylation and Prevents Development of Hypertension |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23421989 https://search.proquest.com/docview/1321794473 |
Volume | 112 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bitswEBXpFkpLKb03vaFC34LSWJYT-zFkW5yW9KFkYd-MLEu7oaxdEoey_Zt-YP-hM7ZsK5vQy76YxNiSzTkeaaQzM4S8VWOjMi5DNvb1iMF4rVgUBIZ5WQAW05iR5hjgvPg8jk_Ex9PgtNf75aiWtmU6VD8OxpVcB1U4B7hilOx_INs2CifgN-ALR0AYjv-EcZXjI0flj1S6vISJMCohz1dppcMaTEuYEG9xMlnnMG8MBKKibNUIVMCsqszTBfih0EOxwoBFFLsU68HSVvGZlxu4peqibPTLNvnTxtUdVdsC4NmuK128RbzJg7BaK1srbGBTDLVL0VYOFEvNpucXV84eF_kZA6uUdlKEan03vtzmbLFyZAQX9Ro3Xq6L1F3QwOISPuOd2Wx3qmJ4kNJl6Z46FCeIbOLbjR1tLTgXTAR1XZfWxHvc4fLEMdiYMM8Z_DHb2eGBZYwDy2z-ZQYfxjSeYi2cIRjHke1oN2f3X-64QW7ySRTgWsHx_FO76SV8HjWF__CtbMAZNPTuYDO7U6k9_-gOufu9QMnF5msVceHMm5b3yT3r8NBpzd4HpKfzh-TWwko6HpGflsTUITHtSEw7EtMrJKYNiWlh6B6JaUNiaklMgcTUITEFEtOGxNQhMTbnkvgxOfnwfjmLma0bwhSA7zGZych4UoLzLbhWoVZSB1IKsEF-qGXggwlSkZ9xk2ZGZpMsMhOVCmMwuaQIIv8JOcrhxZ8RKqSBqzMejtJQCGWiMIvCyIzAjRFGerpPhg0Eybc6PUxSudVjL-kwg_9-UmPWJ28aoBIw5Lg7J3NdbDeJ53McHMXE75OnNYJtk9wXHMWNfcJ3IE3qYOk_d_n8Oje9ILe7b_MlOSrXW_0Kpt9l-roi7W_gsN8g |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Histone+Deacetylase+Inhibition+Attenuates+Transcriptional+Activity+of+Mineralocorticoid+Receptor+Through+Its+Acetylation+and+Prevents+Development+of+Hypertension&rft.jtitle=Circulation+research&rft.au=Lee%2C+Hae-Ahm&rft.au=Lee%2C+Dong-Youb&rft.au=Cho%2C+Hyun-Min&rft.au=Kim%2C+Sang-Yeob&rft.date=2013-03-29&rft.pub=American+Heart+Association%2C+Inc&rft.issn=0009-7330&rft.eissn=1524-4571&rft.volume=112&rft.issue=7&rft.spage=1004&rft.epage=1012&rft_id=info:doi/10.1161%2FCIRCRESAHA.113.301071&rft.externalDocID=10.1161%2FCIRCRESAHA.113.301071 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7330&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7330&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7330&client=summon |